Pre-Activity Questions

Currently, how confident are you in your ability to: *

Please use the scale: 1=Not at all confident , 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=Extremely confident

	1	2	3	4	5
Understand the advanced science behind slowing disease progression in multiple sclerosis?	Understand the advanced science behind slowing disease progression in multiple sclerosis? - 1	Understand the advanced science behind slowing disease progression in multiple sclerosis? - 2	Understand the advanced science behind slowing disease progression in multiple sclerosis? - 3	Understand the advanced science behind slowing disease progression in multiple sclerosis? - 4	Understand the advanced science behind slowing disease progression in multiple sclerosis? - 5
Develop data-driven individualized treatment plans for patients with multiple sclerosis?	Develop data-driven individualized treatment plans for patients with multiple sclerosis? - 1	Develop data-driven individualized treatment plans for patients with multiple sclerosis? - 2	Develop data-driven individualized treatment plans for patients with multiple sclerosis? - 3	Develop data-driven individualized treatment plans for patients with multiple sclerosis? - 4	Develop data-driven individualized treatment plans for patients with multiple sclerosis? - 5

Which of the following is gut microbiota a major modulator of? *

Immune System

Muscular System

Digestive System

Nervous System

Which of the following represents the rate of clinical conversion for adults with Radiologic Isolated Syndrome? *

5 years – 50%

3 years – 50%

5 years – 30%

3 years – 30%

Which of the following represents the rate of clinical conversion for children with Radiologic Isolated Syndrome? *

3 years – 50%

2 years – 50%

2 years – 30%

3 years – 30%

Which of the following is a factor in risk mitigation? *

Time on therapy

Evidence of exposure to the virus

Prior immune-suppression

All of the above

The clinical trial comparing daclizumab given subcutaneously once a month to interferon intramuscular given once weekly showed what percentage of reduction in annualized relapse rate with daclizumab? *

15% reduction

30% reduction

45% reduction

60% reduction

Which of the following therapies showed the best outcomes on NEDA phase III? *

Ocrelizumab

Alemtuzumab

Rituximab

Natalizumab

True or False: A majority of patients using the alemtuzumab therapy required additional rounds of therapies after one year of treatment. *

True

False

Please take a moment to reflect on your current use of the practice strategies discussed in this activity. You will not be graded on your responses.

Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with multiple sclerosis. *

Your Current Use: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, 6=N/A

	1	2	3	4	5	6
Consider the dietary intake of patients with multiple sclerosis.	Consider the dietary intake of patients with multiple sclerosis. - 1	Consider the dietary intake of patients with multiple sclerosis. - 2	Consider the dietary intake of patients with multiple sclerosis. - 3	Consider the dietary intake of patients with multiple sclerosis. - 4	Consider the dietary intake of patients with multiple sclerosis. - 5	Consider the dietary intake of patients with multiple sclerosis. - 6
Implement data-driven treatment plans for multiple sclerosis to effectively address patient-specific characteristics	Implement data-driven treatment plans for multiple sclerosis to effectively address patient-specific characteristics - 1	Implement data-driven treatment plans for multiple sclerosis to effectively address patient-specific characteristics - 2	Implement data-driven treatment plans for multiple sclerosis to effectively address patient-specific characteristics - 3	Implement data-driven treatment plans for multiple sclerosis to effectively address patient-specific characteristics - 4	Implement data-driven treatment plans for multiple sclerosis to effectively address patient-specific characteristics - 5	Implement data-driven treatment plans for multiple sclerosis to effectively address patient-specific characteristics - 6
Effectively educate patients on their personalized treatment plans to improve adherence	Effectively educate patients on their personalized treatment plans to improve adherence - 1	Effectively educate patients on their personalized treatment plans to improve adherence - 2	Effectively educate patients on their personalized treatment plans to improve adherence - 3	Effectively educate patients on their personalized treatment plans to improve adherence - 4	Effectively educate patients on their personalized treatment plans to improve adherence - 5	Effectively educate patients on their personalized treatment plans to improve adherence - 6

Leave this field blank

Elsevier CME

AAN 2016: Implementing Disease Modifying Therapies in the Management of Patients with Multiple Sclerosis

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

30 Day Survey

Course navigation

You are here

AAN 2016: Implementing Disease Modifying Therapies in the Management of Patients with Multiple Sclerosis

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

30 Day Survey

Course navigation